Strengthening Services to Prevent the Infectious Disease Consequences of Drug Use

This contract aims to enhance services that prevent infectious disease outcomes linked to drug use in high-impact settings serving people who use drugs by implementing two interconnected components. The first component focuses on strengthening data collection through biennial surveys of service settings to evaluate capacity, needs, access, and gaps in care, while also gathering biobehavioral data directly from people who use drugs to track trends in infectious disease testing, treatment, and prevention. The second component is designed to expand the availability and utilization of critical services including testing and treatment for hepatitis B, hepatitis C, and HIV within these settings. Applicants may choose to apply for one or both components, with the goal of building a more responsive national and local infrastructure informed by timely, accurate data. Expected outcomes include improved capacity to use data to guide public health interventions, higher rates of testing for hepatitis B, hepatitis C, and HIV among people who use drugs, increased initiation of hepatitis C treatment, and greater engagement in HIV care and treatment. The initiative aligns with CDC priorities and is administered by the Centers for Disease Control and Prevention’s National Center for HIV, Viral Hepatitis, STD, and TB Prevention under the Department of Health and Human Services. The posting date is July 24, 2026, with point of contact information provided for inquiries, and no set-aside or NAICS code has been specified. The funding opportunity is open to applicants prepared to operate in high-impact areas with significant drug use and infectious disease burdens.